Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (36)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rodenhuis, S.
Right arrow Articles by Richel, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodenhuis, S.
Right arrow Articles by Richel, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 3:855-860, 1992
© 1992 European Society for Medical Oncology

research-article

Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantion incorporating carboplatin, cyclophosphamide and thiotepa

S. Rodenhuis1,, J. W. Baars2, J. H. Schoraagel1, L. T. Vlasveld1, I. Mandjes1, H. M. Pinedo1 and D. J. Richel2

1Division of Clinical Oncology, The Netherlands Cancer Institute Amsterdam
2Department of Medical Oncology, Free University Hospital Amsterdam, The Netherlands

Sjoerd Rodenhuis, M.D. Department of Medical Oncology The Netherlands Cancer Institute Plesmanlaan 121 1066 CX Amsterdam The Netherlands

Sixteen patients received a high-dose chemotherapy regimen consisting of carboplatin (1600 mg/m2) and cyclophosphamide (6000 mg/m2) as daily two-hour infusions over four days (CC). All but two of them also received thiotepa (480 mg/m2) in eight 30-minute infusions given every 12 hours (CTC). Bone marrow and/or peripheral stem cell (PSC) reinfusions took place 72 hours after the last course of chemotherapy. The major toxicity was bone marrow suppression, the duration of which was markedly reduced in the patients receiving PSC reinfusions. Non-hematological toxicity was relatively mild and consisted of nausea and vomiting, minor mucositis and skin rashes. All but one patient had mild and completely reversible elevations of serum ALAT and/or LDH levels. One patient, who had received full-dose chemotherapy despite a creatinine clearance of 56 ml/min, developed significant toxicity consisting of transient cyclophosphamide-associated pancarditis, reversible neurotoxicity and partially reversible hearing loss and renal function impairment. There were no toxic deaths. In view of the high carboplatin dose, the CTC regimen may be particularly suitable for use in the salvage treatment of germ cell cancer. Since CTC causes no serious organ toxicity, further studies to determine its suitability for double or even triple transplantation programs are warranted.

carboplatin, cyclophosphamide, thiotepa, autologous, bone marrow transplantation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Rodenhuis, M. Bontenbal, Q. G. C. M. van Hoesel, W. M. Smit, M. A. Nooij, E. E. Voest, E. van der Wall, P. Hupperets, H. van Tinteren, J. L. Peterse, et al.
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer
Ann. Onc., April 1, 2006; 17(4): 588 - 596.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Rodenhuis, M. Bontenbal, L. V.A.M. Beex, J. Wagstaff, D. J. Richel, M. A. Nooij, E. E. Voest, P. Hupperets, H. van Tinteren, H. L. Peterse, et al.
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
N. Engl. J. Med., July 3, 2003; 349(1): 7 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. G. Schrama, I. F. Faneyte, J. H. Schornagel, J. W. Baars, J. L. Peterse, M. J. van de Vijver, O. Dalesio, H. van Tinteren, E. J. T. Rutgers, D. J. Richel, et al.
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up
Ann. Onc., May 1, 2002; 13(5): 689 - 698.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. D. R. Huitema, M. Spaander, R. A. A. Mathot, M. M. Tibben, M. J. Holtkamp, J. H. Beijnen, and S. Rodenhuis
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin
Ann. Onc., March 1, 2002; 13(3): 374 - 384.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Voermans, M. L. K. Kooi, S. Rodenhuis, H. van der Lelie, C. E. van der Schoot, and W. R. Gerritsen
In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation
Blood, February 1, 2001; 97(3): 799 - 804.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Rodenhuis
The Status of High-Dose Chemotherapy in Breast Cancer
Oncologist, October 1, 2000; 5(5): 369 - 375.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.